Esophageal Adenocarcinoma
118
40
51
30
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
20 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.9%
14 terminated out of 118 trials
68.2%
-18.3% vs benchmark
5%
6 trials in Phase 3/4
67%
20 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (118)
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer
Obeticholic Acid for Prevention in Barrett's Esophagus
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Trans-Oral Sampling as an Alternative Surveillance of Barrett's Esophagus Pilot
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma